{"id":"allo-apz2-ots","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Headache"},{"rate":"5-10%","effect":"Nausea"},{"rate":"5-10%","effect":"Diarrhea"}]},"_chembl":{"chemblId":"CHEMBL472440","moleculeType":"Small molecule","molecularWeight":"262.30"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By binding to S1PR1, allo-APZ2-OTS modulates the immune response and has shown potential in treating autoimmune diseases. The exact mechanism of action is still being researched, but it is believed to involve the regulation of immune cell trafficking and function.","oneSentence":"Allo-APZ2-OTS is a small molecule that targets the sphingosine-1-phosphate receptor 1 (S1PR1).","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:00:52.614Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Multiple sclerosis"}]},"trialDetails":[{"nctId":"NCT05838092","phase":"PHASE3","title":"Allogeneic ABCB5-positive Dermal Mesenchymal Stromal Cells for Treatment of Epidermolysis Bullosa (Phase III)","status":"ACTIVE_NOT_RECRUITING","sponsor":"RHEACELL GmbH & Co. KG","startDate":"2023-10-18","conditions":"Epidermolysis Bullosa","enrollment":9},{"nctId":"NCT05464381","phase":"PHASE3","title":"Allogeneic ABCB5-positive Dermal Mesenchymal Stromal Cells for Treatment of Epidermolysis Bullosa (Phase III, Cross-over)","status":"ACTIVE_NOT_RECRUITING","sponsor":"RHEACELL GmbH & Co. KG","startDate":"2023-06-13","conditions":"Epidermolysis Bullosa","enrollment":91}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"allo-APZ2-OTS","genericName":"allo-APZ2-OTS","companyName":"RHEACELL GmbH & Co. KG","companyId":"rheacell-gmbh-co-kg","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Allo-APZ2-OTS is a small molecule being studied in a Phase III clinical trial for the treatment of Epidermolysis Bullosa. The trial is a double-blind, randomized, placebo-controlled study that involves the administration of allo-APZ2-OTS to patients with Epidermolysis Bullosa.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}